You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: August 2020 to June 2022

AbstractFullPdf
Aug 2020562561225
Sep 202021421480
Oct 202010910944
Nov 2020666638
Dec 2020808037
Jan 2021777631
Feb 2021656538
Mar 2021575740
Apr 2021868640
May 2021515142
Jun 2021606042
Jul 2021515137
Aug 2021595946
Sep 2021979760
Oct 2021696949
Nov 2021787868
Dec 2021404229
Jan 2022606549
Feb 2022515741
Mar 2022747746
Apr 2022778033
May 2022667636
Jun 2022535522
Total220222311173